Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess it’s time to diversify to papier-mache stocks that do the ABeta removal! ANAVEX only cures dementia. Looks like BIIB and SAVA need shareholders after their pump. Get taken to the cleaners.
So I guess they usually buy SAVA stock with someone else’s money?
Non substantive implies it’s nothing
Wall Street is just pumped up it’s own fantasy about AVXL and SAVA. Living in dreamland. The reality is in 6 months AVXL will be $200 and heading toward $2000! SAVA will be a jumping bean no one gives a care about.
Fraudulent 2006 data was used by Biogen to justify its claim hence itself was fraudulent.
Those “long’s” are so “diversified” that they own more BIIB & SAVA by 100x than AVXL!
Stupidity is no excuse for fraud! The supporters of fraud cannot be given any credit!
After the purveyors of the fraudulent amyloid hypothesis are eliminated, ie, BIIB and SAVA and others, the phenomenal results will shine. AVXL will be a $400 stock before AVXL A 2-73 approval. After approval, it will slowly rise with revenue to a value greater than $1000.00.
It is now clear that shorts of ANAVEX and the mm of AVXL market all are supporters of the debunked and fraudulent amyloid hypothesis which was made up to support BIIB and SAVA stocks. So that will disappear when prosecuted and when approval is withdrawn from ADUHELM by the FDA! The MOA of ANAVEX A 2-73 is upstream from the cellular remedial action that it causes by merely effectively and safely activating the Sigma 1 receptor!
Hey man aren’t you diversified? You gotta have some honestly run companies and some dishonestly run companies. That’s what Wall Street wants!
Why has the approval of ADUHELM be allowed to stand when it was justified using fraudulent data and was called out as such by a panel of independent experts prior to FDA approval! Where is justice!
We should not allow the charade to go on! ANAVEX is operating at a very high level of credibility with integrity and honesty. The companies that depend on just the amyloid hypothesis have been debunked for fraud; these are BIIB and SAVA. This has been going on for 30 years and we should demand criminal prosecution now. Why are BIIB and SAVA allowed valuations which are so highly maintained when they act criminally.
All that loose fishing line will be reeled in at speeds faster than sound after A 2-73 is approved. Because when revenue is present that will drive MC valuation. The mm no longer has the “no revenue implies no value” plug to drive sp to zero! Revenue directly determines stock price (sp).
Most every drug ever has been based on the now debunked A-Beta theory. The ANAVEX MOA is based on effective Sigma1 activation. Also A 2-73 has had 7 years of very good safety trials. ANAVEX is a new upstream acting technology, effective and safe!
Hey Leo. You say you cannot believe beyond sp of 20 or 30. If ANAVEX does get approval of A 2-73 for ALZHEIMERS, and given that eventual revenue will be between $13B and $68B per year, how do you determine the sp or MC in that situation? In my estimation the sp will be considerably above $1000!
They all believe it is not required for approval. Dr M has said just that!
Even Bo knows!
I believe that belief in ANAVEX science is so widespread that it will be impossible for any investor to buyout ANAVEX for anything less than $1249.00 sp! No one could win shareholders votes!
The P3 AD TLD will report soon, it is known. Probably well after meetings that disclose TLD to the FDA! The FDA are already aware of the outstanding improvements that A 2-73 has made with patients with RETT SYNDROME and PARKINSON’S DISEASE DIMENTIA! The demand for a safe and effective treatment for all three will be an effective force for approval that the FDA cannot ignore!
As it has already become clear from the science that ANAVEX is several years ahead of any other company in the race to find a therapeutic treatment that improves ALZHEIMER’S patients, the low sp will be impossible to manipulate and maintain. The sp is going much higher. Look for 15, 20, … ,100, …, 1000, … , 10000, …
Much better to wait for Dr M to reveal the P3 AD TLD, rather than to just wild guess about the results of the APOEx variants. Your statements have no value, TLD RESULTS will.
AVXL data is already is more than good. The message is already on the wall (street) in neon.
None of the catalysts are now included in the current price of AVXL! It has been iron fist short manipulated for several years. That will change. P3 AD TLD will happen most any day now!
Sure? Dead? Everyone knows that AVXL is a Moon shot rocket on the launch pad with LOX loaded and crew ready. Nice to know that peso misto still believes launch is a year away? TLD is now just anyday!
Papier-mâché PUMP!
The schedule is what it is. It is published schedule and reasonable! Progress is real with ANAVEX, and results are positive! ANAVEX accomplished more with 20 employees working in CNS diseases than any BP company with 10000 employees has previously in 30 years.
Everyone knows that $1249 AVXL share price will occur shortly after revenue begins. It was established over 5 years ago that revenues for ANAVEX with its totally effective ALZHEIMERS THERAPY will be between $13B and $68B annually! The revenues completely determine the share price after approval! The $1249 figure is a conservative estimate.
Just hammering the same point over and over. Folks that actually own shares feel Missling has done a stellar financial job!
Not much can happen with FDA approval until TLD for P3 AD. Today we know that TLD is scheduled for Fall! That’s either SEPT OR OCT! That’s cause for celebration! Keep the cart configured!
Everyone knows that Dr Missling has the most truthful intentions of any CEO of any company on WALL STREET!
It may be that’s the path of too much unnecessary dilution. We may just need a distributor rather than a partner?
No one who owns shares is complaining!
Actually advertised for P3AD TLD Fall 2022!
At this point, there are no others!
Papier-mâché stocks are SAVA, BIIB, … . These are wall streets honeypots to capture ALZHEIMER investors for the take!
Expect AVXL to produce 100x.
ANAVEX is in position 1. TLD P3 AD in SEPT OR OCT. Patience wins!
Essai, really? You don’t know what you talking about! Hampel went to Eisai , headquartered in Japan.
As Warren Buffett often cites the patient long term investor wins. It really shows the immaturity of the short term trader.
I have only fact filled results to cite! The latest is of course the PDD TRIAL RESULTS! Absolutely jaw dropping facts. With ANAVEX there are no fantasies, the truth of the data results are lasting and will culminate in the TLD reveal of the completed P3 AD TRIAL in September or October.